Apollon Wealth Management LLC Cuts Holdings in Kenvue Inc. (NYSE:KVUE)

Apollon Wealth Management LLC lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 11.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,048 shares of the company’s stock after selling 1,314 shares during the quarter. Apollon Wealth Management LLC’s holdings in Kenvue were worth $232,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Leo Wealth LLC raised its holdings in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after purchasing an additional 481 shares during the period. Massmutual Trust Co. FSB ADV grew its holdings in Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after purchasing an additional 492 shares during the period. Wolff Wiese Magana LLC increased its position in Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after buying an additional 501 shares during the last quarter. Marathon Capital Management raised its stake in shares of Kenvue by 0.3% in the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after buying an additional 514 shares during the period. Finally, Poehling Capital Management INC. lifted its position in shares of Kenvue by 0.5% during the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after buying an additional 547 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.4 %

KVUE opened at $23.73 on Tuesday. The firm has a market capitalization of $45.50 billion, a P/E ratio of 43.15, a price-to-earnings-growth ratio of 2.16 and a beta of 1.36. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.13. The company has a fifty day moving average price of $22.77 and a 200-day moving average price of $20.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the previous year, the business earned $0.31 earnings per share. The firm’s revenue was down .4% on a year-over-year basis. Equities research analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on KVUE shares. JPMorgan Chase & Co. boosted their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Jefferies Financial Group initiated coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft increased their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.